The Azimilide Post-Infarct Survival Evaluation (ALIVE) Trial
- 1 March 1998
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 81 (6) , 35D-39D
- https://doi.org/10.1016/s0002-9149(98)00151-9
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Pharmacology of Azimilide Dihydrochloride (NE‐10064), A Class III Antiarrhythmic AgentCardiovascular Drug Reviews, 1997
- Comparison of the Rate-Dependent Properties of the Class III Antiarrhythmic Agents Azimilide (NE-10064) and E-4031.Journal of Cardiovascular Electrophysiology, 1997
- Azimilide (NE‐10064) Can Prolong or Shorten the Action Potential Duration in Canine Ventricular Myocytes:Journal of Cardiovascular Electrophysiology, 1997
- Use-Dependent Effects of the Class III Antiarrhythmic Agent NE-10064 (Azimilide) on Cardiac RepolarizationJournal of Cardiovascular Pharmacology, 1995
- Survival with oral d-Sotalol in patients with left ventricular dysfunction after myocardial infarction: Rationale, design, and methods (the SWORD trial)The American Journal of Cardiology, 1995
- Comparison of the Cardiac Electrophysiologic Effects of NE-10064 with Sotalol and E-4031 and Their Modification by Simulated IschaemiaJournal of Cardiovascular Pharmacology, 1994
- Protection Against Programmed Electrical Stimulation-Induced Ventricular Tachycardia and Sudden Cardiac Death by NE-10064, a Class III Antiarrhythmic DrugJournal of Cardiovascular Pharmacology, 1993
- Effect of the Antiarrhythmic Agent Moricizine on Survival after Myocardial InfarctionNew England Journal of Medicine, 1992
- Comparison of the predictive characteristics of heart rate variability index and left ventricular ejection fraction for all-cause mortality, arrhythmic events and sudden death after acute myocardial infarctionThe American Journal of Cardiology, 1991
- Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or PlaceboNew England Journal of Medicine, 1991